Physician profile
Phillip Helding
NPI 1043351026
$8,044.14
in general payments reported to CMS, 2019-2025
27 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 81% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $370 · 2021: $1,412 · 2022: $1,485 · 2023: $1,586 · 2024: $1,489 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,236.82 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,203.39 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,033.91 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $836.06 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $701.94 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $662.11 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $493.56 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $396.17 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $328.94 | 2019-2024 | Jornay Pm |
| Corium, LLC | $315.75 | 2021-2025 | Azstarys |
| Alkermes, INC. | $291.54 | 2022-2025 | Lybalvi, Aristada |
| Tris Pharma INC | $273.99 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.00 | 2021-2025 | Caplyta |
| Allergan, INC. | $215.45 | 2019-2020 | |
| Almatica Pharma LLC | $158.81 | 2022 | |
| Neos Therapeutics, Lp | $157.89 | 2019-2024 | Adzenys Xr-Odt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $121.11 | 2019-2022 | |
| Adlon Therapeutics L.P. | $120.88 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $115.43 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $90.12 | 2021-2024 | Xelstrym, Secuado |
| Shire North American Group INC | $77.09 | 2019 | |
| Axsome Therapeutics, INC. | $62.17 | 2023-2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $39.40 | 2022-2023 | Keveyis |
| Jazz Pharmaceuticals INC. | $39.37 | 2021-2022 | |
| Alfasigma USA, INC. | $31.15 | 2021-2022 | |
| Indivior INC. | $19.10 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $16.60 | 2023 | Quviviq |
| Tempus Ai, INC | $15.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Helding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.